InnoCare Pharma Ltd. A (688428) - Total Assets
Based on the latest financial reports, InnoCare Pharma Ltd. A (688428) holds total assets worth CN¥9.36 Billion CNY as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
InnoCare Pharma Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how InnoCare Pharma Ltd. A's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
InnoCare Pharma Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
InnoCare Pharma Ltd. A's total assets of CN¥9.36 Billion consist of 83.1% current assets and 16.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 66.2% |
| Accounts Receivable | CN¥352.90 Million | 3.8% |
| Inventory | CN¥95.58 Million | 1.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥35.92 Million | 0.4% |
| Goodwill | CN¥3.12 Million | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how InnoCare Pharma Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InnoCare Pharma Ltd. A's current assets represent 83.1% of total assets in 2024, a decrease from 90.2% in 2020.
- Cash Position: Cash and equivalents constituted 66.2% of total assets in 2024, down from 87.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
InnoCare Pharma Ltd. A Competitors by Total Assets
Key competitors of InnoCare Pharma Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zelluna ASA
OL:ZLNA
|
Norway | Nkr103.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥9.09 Billion |
InnoCare Pharma Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.57 | 3.82 | 4.48 |
| Quick Ratio | 7.46 | 3.77 | 4.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.81 Billion | CN¥5.96 Billion | CN¥7.22 Billion |
InnoCare Pharma Ltd. A - Advanced Valuation Insights
This section examines the relationship between InnoCare Pharma Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.96 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.2% |
| Total Assets | CN¥9.41 Billion |
| Market Capitalization | $1.21 Billion USD |
Valuation Analysis
Below Book Valuation: The market values InnoCare Pharma Ltd. A's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: InnoCare Pharma Ltd. A's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for InnoCare Pharma Ltd. A (2020–2024)
The table below shows the annual total assets of InnoCare Pharma Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.41 Billion | -5.16% |
| 2023-12-31 | CN¥9.92 Billion | -3.90% |
| 2022-12-31 | CN¥10.32 Billion | +39.52% |
| 2021-12-31 | CN¥7.40 Billion | +63.02% |
| 2020-12-31 | CN¥4.54 Billion | -- |
About InnoCare Pharma Ltd. A
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone l… Read more